PMC9797826_01
Complete timeline for treatment regimens, disease status and patient treatment response.
fonc-12-1071383-g001.jpg
PMC9797826_01_fonc-12-1071383-g001.jpg
f1
NCCN guideline, we gave the patient post-operative chemotherapy, and the timeline of the treatment process is shown in  Figure 1 . No tumor was detected by CT after 6 cycles of TP/TC therapy (175 mg/m2 paclitaxel plus 75/mg2 cisplatin, or 175 mg/m2 paclitaxel plus carboplatin area under the curve (AUC) 5), so she was considered to have achieved complete clinical response (CR).
MRI images of local recurrent lesions during treatment. (A) Local recurrence of the last progression (January 2019). (B) MRI images after the last 6 cycles of non-platinum-based chemotherapy combined with bevacizumab (July 2021). (C) MRI images of 12 months after maintenance treatment using the PARP inhibitor Olaparib (July 2022).
fonc-12-1071383-g002.jpg
PMC9797826_01_fonc-12-1071383-g002.jpg
f2
Magnetic resonance imaging (MRI) and [18F] fluorodeoxyglucose (FDG) -positron emission tomography (PET) showed that there was a mass on the right side of the vaginal stump and the right posterior rectal wall, accompanied by increased glucose metabolism ( Figure 2A ). In  Figure 2 , we display the radiographic changes occurred in our patient during treatment.
Three-dimensional conformal dose assessment for interstitial BT. (A). Cross-sectional image. (B). Sagittal image. (C). Coronal image. (D). Dose-volume histogram (DVH).
fonc-12-1071383-g003.jpg
PMC9797826_01_fonc-12-1071383-g003.jpg
f3
Figure 3  shows the three-dimensional conformal dose assessment for interstitial brachytherapy. Following the completion of radiotherapy, the patient received individual therapy with PARP inhibitor (olaparib) for maintenance due to homologous recombination deficiency (HRD).
Changes in serum CA125 and HE4 levels during the whole process of treatment.
fonc-12-1071383-g004.jpg
PMC9797826_01_fonc-12-1071383-g004.jpg
f4
Currently, the patient remained in CR at the last imaging follow-up in July 2022, even though tumor markers (serum CA125 and HE4) had started to slowly increase ( Figure 4 ).